WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H592546
CAS#: 129448-97-1
Description: RB 6145 is an anticancer drug.
Hodoodo Cat#: H592546
Name: RB 6145
CAS#: 129448-97-1
Chemical Formula: C8H14Br2N4O3
Exact Mass: 371.94
Molecular Weight: 374.030
Elemental Analysis: C, 25.69; H, 3.77; Br, 42.73; N, 14.98; O, 12.83
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: RB 6145; RB-6145; RB6145
IUPAC/Chemical Name: 1H-Imidazole-1-ethanol, alpha-(((2-bromoethyl)amino)methyl)-2-nitro-, monohydrobromide
InChi Key: XPBJPGMCFKYBBV-UHFFFAOYSA-N
InChi Code: InChI=1S/C8H13BrN4O3.BrH/c9-1-2-10-5-7(14)6-12-4-3-11-8(12)13(15)16;/h3-4,7,10,14H,1-2,5-6H2;1H
SMILES Code: OC(Cn1c([N+]([O-])=O)ncc1)CNCCBr.Br
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 374.03 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Winters T, Sercel A, Suto C, Elliott W, Leopold W, Leopold J, Showalter H. Design and synthesis of 2-nitroimidazoles with variable alkylating and acylating functionality. Chem Pharm Bull (Tokyo). 2014;62(3):301-3. PubMed PMID: 24583786.
2: Lunt SJ, Cawthorne C, Ali M, Telfer BA, Babur M, Smigova A, Julyan PJ, Price PM, Stratford IJ, Bloomer WD, Papadopoulou MV, Williams KJ. The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy. Br J Cancer. 2010 Jul 13;103(2):201-8. doi: 10.1038/sj.bjc.6605753. Epub 2010 Jun 29. PubMed PMID: 20588272; PubMed Central PMCID: PMC2906743.
3: Miller TJ, Schneider RJ, Miller JA, Martin BP, Al-Ubaidi MR, Agarwal N, Dethloff LA, Philbert MA. Photoreceptor cell apoptosis induced by the 2-nitroimidazole radiosensitizer, CI-1010, is mediated by p53-linked activation of caspase-3. Neurotoxicology. 2006 Jan;27(1):44-59. Epub 2005 Aug 24. PubMed PMID: 16125243.
4: Lunt SJ, Telfer BA, Fitzmaurice RJ, Stratford IJ, Williams KJ. Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination. Clin Cancer Res. 2005 Jun 1;11(11):4212-6. PubMed PMID: 15930359.
5: Miller TJ, Phelka AD, Tjalkens RB, Dethloff LA, Philbert MA. CI-1010 induced opening of the mitochondrial permeability transition pore precedes oxidative stress and apoptosis in SY5Y neuroblastoma cells. Brain Res. 2003 Feb 14;963(1-2):43-56. PubMed PMID: 12560110.
6: Olive PL, Banáth JP, Durand RE. The range of oxygenation in SiHa tumor xenografts. Radiat Res. 2002 Aug;158(2):159-66. PubMed PMID: 12105985.
7: Patterson AV, Williams KJ, Cowen RL, Jaffar M, Telfer BA, Saunders M, Airley R, Honess D, van der Kogel AJ, Wolf CR, Stratford IJ. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther. 2002 Jul;9(14):946-54. PubMed PMID: 12085243.
8: Lee AE, Wilson WR. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol. 2000 Feb 15;163(1):50-9. PubMed PMID: 10662604.
9: Breider MA, Ulloa HM, Pegg DG, Gough AW. Nitro-imidazole radiosensitizer-induced toxicity in cynomolgus monkeys. Toxicol Pathol. 1998 Sep-Oct;26(5):651-6. PubMed PMID: 9789952.
10: Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer. 1998 Aug;78(4):439-45. PubMed PMID: 9716024; PubMed Central PMCID: PMC2063102.
11: Breider MA, Pilcher GD, Graziano MJ, Gough AW. Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol Pathol. 1998 Mar-Apr;26(2):234-9. PubMed PMID: 9547861.
12: Bullen WW, Rossi DT, Hoffman KL, Suri A, Lathia CD. An HPLC assay utilizing solid-phase extraction for CI-1010, an alkylating radiosensitizer, in rat plasma. J Pharm Biomed Anal. 1997 Sep;16(1):47-55. PubMed PMID: 9447551.
13: Skarsgard LD, Wouters BG. Substructure in the cell survival response at low radiation dose: effect of different subpopulations. Int J Radiat Biol. 1997 Jun;71(6):737-49. PubMed PMID: 9246187.
14: Butler SA, Wood PJ, Cole S, Williams C, Adams GE, Stratford IJ. Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase. Br J Cancer. 1997;76(4):438-44. PubMed PMID: 9275019; PubMed Central PMCID: PMC2227976.
15: Hay MP, Denny WA, Wilson WR. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins. Anticancer Drug Des. 1996 Jul;11(5):383-402. PubMed PMID: 8765531.
16: Horsman MR, Chaplin DJ, Hill SA, Arnold S, Collingridge D, Radacic M, Wood PJ, Overgaard J. Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours. Br J Cancer Suppl. 1996 Jul;27:S168-71. PubMed PMID: 8763873; PubMed Central PMCID: PMC2150003.
17: Wilson WR, Denny WA, Pullen SM, Thompson KM, Li AE, Patterson LH, Lee HH. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Br J Cancer Suppl. 1996 Jul;27:S43-7. PubMed PMID: 8763844; PubMed Central PMCID: PMC2149993.
18: Wood PJ, Horsman MR, Khalil AA, Steinberg F, Streffer C, Overgaard J, Stratford IJ, Adams GE. A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour. Acta Oncol. 1996;35(8):989-94. PubMed PMID: 9023383.
19: Skarsgard LD, Acheson DK, Vinczan A, Wouters BG, Heinrichs BE, Loblaw DA, Minchinton AI, Chaplin DJ. Cytotoxic effect of RB 6145 in human tumour cell lines: dependence on hypoxia, extra- and intracellular pH and drug uptake. Br J Cancer. 1995 Dec;72(6):1479-86. PubMed PMID: 8519663; PubMed Central PMCID: PMC2034082.
20: Moselen JW, Hay MP, Denny WA, Wilson WR. N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug. Cancer Res. 1995 Feb 1;55(3):574-80. PubMed PMID: 7834627.
